- PR Newswire•17 days ago
LA JOLLA, Calif., Oct. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
- PR Newswire•18 days ago
"Tim brings over 30 years of academic and industry experience that includes leading worldwide clinical development programs," said Paul C. Grint, M.D., President and CEO. "His expertise in translational research will enable us to significantly advance and develop our pipeline.
Regulus Therapeutics Inc. (RGLS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||2.84 x 400|
|Ask||3.91 x 300|
|Day's Range||2.70 - 2.92|
|52wk Range||2.44 - 10.60|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.38|
|Avg Vol (3m)||420,592|
|Dividend & Yield||N/A (N/A)|